Free Trial

HLS Therapeutics (HLS) Stock Forecast & Price Target

C$3.34
+0.13 (+4.06%)
(As of 07/19/2024 ET)

HLS Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 4 Wall Street analysts who have issued ratings for HLS Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 4 analysts, 3 have given a hold rating, and 1 has given a buy rating for HLS.

Consensus Price Target

C$3.88
16.19% Upside
High ForecastC$4.00
Average ForecastC$3.88
Low ForecastC$3.75

According to the 4 analysts' twelve-month price targets for HLS Therapeutics, the average price target is C$3.88. The highest price target for HLS is C$4.00, while the lowest price target for HLS is C$3.75. The average price target represents a forecasted upside of 16.19% from the current price of C$3.34.

TypeCurrent Forecast
7/22/23 to 7/21/24
1 Month Ago
6/22/23 to 6/21/24
3 Months Ago
4/23/23 to 4/22/24
1 Year Ago
7/22/22 to 7/22/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetC$3.88C$3.88C$4.58C$19.80
Forecasted Upside16.19% Upside-16.08% Downside-0.05% Downside51.09% Upside
Get HLS Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter.

HLS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HLS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

HLS Therapeutics Stock vs. The Competition

TypeHLS TherapeuticsMedical Companies
Consensus Rating Score
2.25
2.72
Consensus RatingHoldModerate Buy
News Sentiment RatingNeutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/10/2024Raymond James
4 of 5 stars
 Lower TargetC$5.00 ➝ C$4.00-3.61%
5/10/2024Stifel Nicolaus
4 of 5 stars
 Lower TargetC$4.15 ➝ C$3.75-9.64%
2/6/2024Clarus Securities
5 of 5 stars
G. Ulybyshev
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
11/9/2023Stifel Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Keywood
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/17/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$21.75 ➝ C$17.50+175,000,000.00%
7/26/2022Bloom Burton
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyC$22.00+66.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 03:16 PM ET.

HLS Forecast - Frequently Asked Questions

What is HLS Therapeutics' forecast for 2024?

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for HLS Therapeutics is C$3.88, with a high forecast of C$4.00 and a low forecast of C$3.75.

Should I buy or sell HLS Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLS, but not buy additional shares or sell existing shares.

Does HLS Therapeutics's stock price have much downside?

According to analysts, HLS Therapeutics's stock has a predicted downside of -16.08% based on their 12-month stock forecasts.

What analysts cover HLS Therapeutics?

HLS Therapeutics has been rated by research analysts at Raymond James, and Stifel Nicolaus in the past 90 days.

Do Wall Street analysts like HLS Therapeutics more than its competitors?

Analysts like HLS Therapeutics less than other "medical" companies. The consensus rating for HLS Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HLS compares to other companies.


This page (TSE:HLS) was last updated on 7/21/2024 by MarketBeat.com Staff

From Our Partners